Neovasc Inc.

Recent News

  • Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 19, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral ...

    2019-11-19 9:00 AM ET
  • Neovasc Reducer(TM) Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

    Vancouver, British Columbia and Mainz, Germany--(Newsfile Corp. - November 12, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced ...

    2019-11-12 7:00 AM ET
  • Neovasc Announces Third Quarter 2019 Financial Results

    Recent HighlightsDelivered continued revenue growth for Neovasc ReducerTM ("Reducer")Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory anginaReducer featured at the 40th Annual National Congress of the Italian Society of Interventional CardiologyAnnounced Norman Radow joined the board of directorsGranted a US patent coverin

    2019-11-07 4:05 PM ET
  • Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer

    Vancouver, British Columbia--(Newsfile Corp. - November 7, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment ...

    2019-11-07 7:00 AM ET
  • Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum

    Vancouver, British Columbia--(Newsfile Corp. - November 6, 2019) - Neovasc, Inc. (TSX: NASDAQ) (TSX: NVCN) ("Neovasc" or the "Company") a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred ...

    2019-11-06 8:30 AM ET
  • Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 5, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the ...

    2019-11-05 7:00 AM ET
  • Neovasc to Submit Full PMA Application for Neovasc Reducer(TM) in 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 1, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it intends ...

    2019-11-01 7:30 AM ET
  • Neovasc to Participate in the 28th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019

    Vancouver, British Columbia--(Newsfile Corp. - October 30, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO ...

    2019-10-30 9:24 AM ET